Cargando…
501. Risk Factors for Persistent Active COVID-19 Among Patients Receiving B-Cell Depleting Therapy versus Non-B-Cell Immunosuppression
BACKGROUND: Cases of COVID-19 characterized by prolonged replication of SARS-CoV-2 (persistent active COVID [PAC]) have been reported among immunocompromised patients, particularly those receiving B-cell depleting therapy (BCDT); however, the risk has not been quantified. We aimed to identify risk f...
Autores principales: | Voll, Kevin, Kartes, Jacob, Spivak, Emily S, Imlay, Hannah |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677509/ http://dx.doi.org/10.1093/ofid/ofad500.570 |
Ejemplares similares
-
493. Incidence and Characterization of Chronic Active COVID Among Patients Infected with the Novel Coronavirus (COVID-19) Receiving B-cell Depleting Therapies (BCDTs)
por: Kartes, Jacob, et al.
Publicado: (2021) -
140. Follow-up Blood Cultures for Gram-Negative Bacteremia among Adults with Cancer
por: Haak, David, et al.
Publicado: (2023) -
1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes
por: Fenlon, Luke A, et al.
Publicado: (2023) -
456. Within-host Viral Evolution and Neutralizing Antibody Response in Immunocompromised Patients with Persistent SARS-CoV-2 Infection Receiving B Cell Depleting Treatment
por: Ahn, Sangmin, et al.
Publicado: (2023) -
Evaluation of Antibody and T Cell Responses to COVID-19 Vaccination in Patients with Lymphoid Malignancies Receiving B Cell-Depleting Agents
por: Goel, Shipra, et al.
Publicado: (2022)